How early should psoriatic arthritis be treated with a TNF-blocker?

Hdl Handle:
http://hdl.handle.net/10147/207498
Title:
How early should psoriatic arthritis be treated with a TNF-blocker?
Authors:
Harty, Leonard; Veale, Douglas James
Affiliation:
Dublin Academic Medical Centre, Department of Rheumatology, St Vincent's, University Hospital, University College Dublin, Dublin, Ireland.
Citation:
Curr Opin Rheumatol. 2010 Jul;22(4):393-6.
Journal:
Current opinion in rheumatology
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207498
DOI:
10.1097/BOR.0b013e32833a3d42
PubMed ID:
20520552
Abstract:
PURPOSE OF REVIEW: Psoriatic arthritis (PsA) is the second most commonly identified inflammatory arthropathy in early arthritis clinics. It is a complex multisystem disease involving the skin and joints, but may also present with inflammation of the spine - spondylitis, digits - dactylitis, eyes - uveitis and ligamentous insertions - enthesitis. The skin manifestations may be mild or patchy and often precede the joint inflammation. Joint erosions, however, may occur within the first 2 years in up to half of PsA patients and an erosion rate of 11% per annum has been reported suggesting it is not a benign disease as it was once regarded. RECENT FINDINGS: Therapy with mild anti-inflammatories is only beneficial in very mild or localized disease. In cases of more widespread joint involvement systemic therapy with disease-modifying antirheumatic drugs (DMARDs) such as methotrexate may be required and in the case of extra-articular or spinal disease, in which DMARDs have failed to show efficacy, biologic therapy may be highly effective. SUMMARY: The question of how early treatment should be instituted should be decided in a specialist rheumatology referral centre following appropriate assessment. Optimal therapy with combination DMARD and biologics may result in remission rates of up to 60%.
Language:
eng
MeSH:
Antibodies, Monoclonal/*therapeutic use; Antirheumatic Agents/therapeutic use; Arthritis, Psoriatic/*therapy; Humans; Receptors, Tumor Necrosis Factor/*antagonists & inhibitors; Tumor Necrosis Factor-alpha/therapeutic use
ISSN:
1531-6963 (Electronic); 1040-8711 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorHarty, Leonarden_GB
dc.contributor.authorVeale, Douglas Jamesen_GB
dc.date.accessioned2012-02-01T10:29:33Z-
dc.date.available2012-02-01T10:29:33Z-
dc.date.issued2012-02-01T10:29:33Z-
dc.identifier.citationCurr Opin Rheumatol. 2010 Jul;22(4):393-6.en_GB
dc.identifier.issn1531-6963 (Electronic)en_GB
dc.identifier.issn1040-8711 (Linking)en_GB
dc.identifier.pmid20520552en_GB
dc.identifier.doi10.1097/BOR.0b013e32833a3d42en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207498-
dc.description.abstractPURPOSE OF REVIEW: Psoriatic arthritis (PsA) is the second most commonly identified inflammatory arthropathy in early arthritis clinics. It is a complex multisystem disease involving the skin and joints, but may also present with inflammation of the spine - spondylitis, digits - dactylitis, eyes - uveitis and ligamentous insertions - enthesitis. The skin manifestations may be mild or patchy and often precede the joint inflammation. Joint erosions, however, may occur within the first 2 years in up to half of PsA patients and an erosion rate of 11% per annum has been reported suggesting it is not a benign disease as it was once regarded. RECENT FINDINGS: Therapy with mild anti-inflammatories is only beneficial in very mild or localized disease. In cases of more widespread joint involvement systemic therapy with disease-modifying antirheumatic drugs (DMARDs) such as methotrexate may be required and in the case of extra-articular or spinal disease, in which DMARDs have failed to show efficacy, biologic therapy may be highly effective. SUMMARY: The question of how early treatment should be instituted should be decided in a specialist rheumatology referral centre following appropriate assessment. Optimal therapy with combination DMARD and biologics may result in remission rates of up to 60%.en_GB
dc.language.isoengen_GB
dc.subject.meshAntibodies, Monoclonal/*therapeutic useen_GB
dc.subject.meshAntirheumatic Agents/therapeutic useen_GB
dc.subject.meshArthritis, Psoriatic/*therapyen_GB
dc.subject.meshHumansen_GB
dc.subject.meshReceptors, Tumor Necrosis Factor/*antagonists & inhibitorsen_GB
dc.subject.meshTumor Necrosis Factor-alpha/therapeutic useen_GB
dc.titleHow early should psoriatic arthritis be treated with a TNF-blocker?en_GB
dc.contributor.departmentDublin Academic Medical Centre, Department of Rheumatology, St Vincent's, University Hospital, University College Dublin, Dublin, Ireland.en_GB
dc.identifier.journalCurrent opinion in rheumatologyen_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.